PIRADS Calculator v. 2.1
A joint effort by ACR, AdMeTech Foundation, and ESUR
Lesion-level chance of malignancy per PI‐RADS® v2.1 score, according to Oerther et al. ²:
- PI-RADS 1 – Very low (~2%)
- PI-RADS 2 – Low (~4%)
- PI-RADS 3 – Intermediate (~20%)
- PI-RADS 4 – High (~52%)
- PI-RADS 5 – Very high (~89%)
References:
- Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340-351. doi:10.1016/j.eururo.2019.02.033
- Oerther B, Engel H, Bamberg F, Sigle A, Gratzke C, Benndorf M. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis. 2022;25(2):256-263. doi:10.1038/s41391-021-00417-1
Related Calculators:
More about the PI-RADS v2.1 Calculator:
The Prostate Imaging Reporting and Data System (PI-RADS), currently in version 2.1, is an internationally recognized framework developed to standardize the interpretation and reporting of prostate MRI findings. While our interactive PI-RADS v2.1 calculator is not officially endorsed by the American College of Radiology (ACR), it aims to support the clinical application of this system by streamlining risk assessment and decision-making in prostate imaging.
PI-RADS is designed to improve the detection, localization, and risk stratification of prostate cancer through multiparametric MRI (mpMRI), which includes T2-weighted imaging, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) imaging. The system assigns scores to specific prostate zones based on imaging findings, resulting in a comprehensive risk category that guides clinical management. This framework ensures consistent evaluation across diverse practice settings, aiding communication between radiologists, urologists, and oncologists.
The PI-RADS v2.1 calculator automates this scoring process, offering an intuitive platform to assess prostate lesions based on the PI-RADS lexicon. By integrating the structured criteria from PI-RADS v2.1, the calculator simplifies lesion evaluation, ensuring a standardized approach that aligns with best practices. It enables healthcare providers to quickly determine the likelihood of clinically significant prostate cancer, improving diagnostic accuracy and patient care.
Using the PI-RADS system in clinical practice enhances consistency and clarity in prostate MRI reporting. By providing a structured framework, it minimizes variability in interpretations, promotes evidence-based risk assessment, and improves coordination among multidisciplinary teams. The interactive calculator further enhances these benefits by making PI-RADS scoring more accessible and user-friendly, reducing the learning curve for new users and saving time for experienced practitioners.
Although not endorsed by the ACR, this calculator aligns with the principles of the PI-RADS initiative by facilitating the adoption of its standardized lexicon. By leveraging the scoring criteria of PI-RADS v2.1, the tool empowers radiologists and clinicians to stratify lesions with confidence and make informed decisions about biopsy and treatment planning. It serves as a valuable resource for integrating PI-RADS into routine clinical workflows, fostering better outcomes for patients undergoing prostate cancer evaluation.
In conclusion, the PI-RADS v2.1 calculator provides a practical solution for implementing a widely accepted prostate imaging framework in clinical practice. Whether used in academic, outpatient, or hospital settings, the calculator supports efficient and accurate prostate lesion assessment. By automating the PI-RADS scoring process, it ensures consistency and precision, helping clinicians deliver high-quality, patient-centered care in prostate cancer diagnostics.
